I would like to see, if we were to use the debt option, enough borrowed to cover four quarters, I definitely would hate to see the CR option, no matter how unlikely that may be.
Not sure another placement would be a good idea either, with the debt option that would give Admedus some much needed breathing space, any increase in income would be a super bonus in this situation, imo, that with capital on hand plus borrowings may turn the tide.
This is a laymans view, mine, seems to make sense to me, but I am not business brain.
That with the clarification on the immunotherapies division may do enough to create a postive sentiment/sp appreciation.
If these two actions still do not alter the current situation I seriously believe Admedus is in trouble!
Answers from WP - a good read, page-157
-
- There are more pages in this discussion • 159 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.49 |
Change
0.490(4.08%) |
Mkt cap ! $264.0M | |||
| Open | High | Low | Value | Volume |
| $12.11 | $12.49 | $11.50 | $155.8K | 13.16K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 175 | $11.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.49 | 77 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| AVR (ASX) Chart |